UCSD Research Team Identifies Novel Anti-Cancer Drug from the Sea

A collaborative team of researchers spearheaded by Dennis Carson, M.D., professor of medicine and director of the Rebecca and John Moores UCSD Cancer Center at the UC San Diego (UCSD) has identified a potent new anti-cancer drug isolated from toxic blue-green algae found in the South Pacific. The properties of somocystinamide A (ScA) are described in a paper that will be published online in Proceedings of the National Academy of Science the week of Feb. 11 -15.

"We are excited because we have discovered a structurally unique and highly potent cancer-fighting compound," said Dwayne Stupack, associate professor of pathology at the Moores UCSD Cancer Center. "We envision it will be perfect for emerging technology, particularly nanotechnology, which is being developed to target cancerous tumors without toxic side effects."

The ScA compound was found in cyanobacteria called L. majuscula, also known as "mermaid's hair," gathered off the coast of Fiji in the South Pacific by the laboratory of William Gerwick at Scripps Institution of Oceanography at UC San Diego. A diverse team of researchers from UCSD's Cancer Center, School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences and Scripps worked to identify, screen and test marine compounds in vitro and in vivo. They found that ScA inhibits neovascularization, the formation of blood vessels that feed tumors, and also had a direct impact on tumor cell proliferation.

"The compound isn't toxic to cyanobacteria, but activates a 'death pathway,' present in our cells," said Stupack. "When the cells of the blood vessels that feed tumors become activated and proliferate, they become especially sensitive to this agent."

Gerwick noted that if a normal-sized swimming pool full of cancer cells were treated with ScA, it would take only three milligrams - about the weight of a grain of rice - to kill all of the cancer cells.

Wolf Wrasidlo, Ph.D., senior project scientist at the Moores UCSD Cancer Center and first author of the work, added that the unique structure of this compound lends itself very well to nanotechnology, because it "incorporates spontaneously" into molecule-sized nanoparticles, important for the kind of highly targeted, combination therapy being developed to treat cancer. The structure is also simple enough that the scientists can reproduce it.

"ScA is the first, and most potent compound we've identified so far," Stupack said, adding that it won't be the last, as the Scripps team has identified more than 250 unique compounds from L. majuscula alone. "But we don't yet know how abundant ScA is, or if it's feasible to harvest, so it is important that we have been able to produce this natural product in the lab."

Contributors to this paper are first authors Wolf Wrasidlo and Ainhoa Mielgo, as well as Vicente A. Torres, Simone Barbero, Konstantin Stoletov, Richard L. Klemke and Dwayne G. Stupack of UCSD's Department of Pathology and Moores UCSD Cancer Center; Takashi L. Suyama of the Skaggs School of Pharmacy and Pharmaceutical Sciences; William H. Gerwick of the Center for Marine Biotechnology and Biomedicine at Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences; and Dennis Carson, Director of the Moores UCSD Cancer Center. The research was funded by grants from the National Cancer Institute, as well as fellowships from the National Swiss Foundation and California Breast Cancer Research.